Ab­b­vie, Prin­cip­ia join forces on im­muno­pro­tea­some in­hibitors; Scripps de­vel­ops hero­in vac­cine, FDA fast tracks NGF pain drug

→ Ab­b­vie and Prin­cip­ia are col­lab­o­rat­ing to de­vel­op oral im­muno­pro­tea­some in­hibitors to treat au­toim­mune dis­ease us­ing nov­el tech­nol­o­gy dis­cov­ered at Prin­cip­ia. Fi­nan­cial terms were …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER